

FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220001/EKS/PAJAPPLICATION NO.  
09/518,383FIRST NAMED INVENTOR  
Li et al.FILING DATE  
March 3, 2000ART UNIT  
1646FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
PM	AE1	2002/0052043 A1	05/02/2002	Li et al.		MAR 01 2004	04/09/2001
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
PM	AN1	WO 91/15583 A1	10/17/1991	WIPO			Yes No
PM	AO1	WO 99/35106 A2	07/15/1999	WIPO			Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
PM	AS	4	Chattaraj, S.C., "Cangrelor AstraZeneca," <i>Curr. Opin. Invest. Drugs</i> 2:250-255, PharmaPress Ltd. (February 2001)
PM	AT	4	Van Brocklyn, J.R., et al., "Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6," <i>Blood</i> 95:2624-2629, The American Society of Hematology (April 2000)


EXAMINER

Prerna Menz

DATE CONSIDERED

9/22/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220001/EKS/PAJAPPLICATION NO.  
09/518,383FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
March 3, 2000ART UNIT  
1646**ADDITIONAL SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

PM	AR	<u>5</u>	Wang, K., <i>et al.</i> , "Blockade of the Platelet P2Y <sub>12</sub> Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model," <i>Arterioscler. Thromb. Vasc. Biol</i> 22:357-362, Lippincott, Williams & Wilkins (February 2003)
PM	AS	<u>5</u>	Database EMBL, Accession No. AA254425, Marra, M., <i>et al.</i> , (first available March 1997)
PM	AT	<u>5</u>	Partial European Search Report for European Application No. 03 01 5456, mailed December 17, 2003, European Patent Office, Netherlands

EXAMINER

Preme Ment

DATE CONSIDERED

9/22/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220001/EKS/PAJ  
FIRST NAMED INVENTOR  
Li et al.APPLICATION NO.  
09/518,383SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTFILING DATE  
March 3, 2000ART UNIT  
1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PM	AR	<u>6</u>	Copy of Co-Pending U.S. Patent Application No. 09/518,381, Li et al., filed March 3, 2000 (NOT PUBLISHED)
	AS		
	AT		

EXAMINER  
Prima Mung

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

9/22/04